Related Experiment Video
Updated: May 15, 2025
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Immunotherapy in chronic lymphocytic leukemia: advances and challenges
Pan Gao1, Yang Zhang1, Jun Ma1
1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, Jinan, Shandong, 250021, China.
Insights
This review examines current immunotherapies for chronic lymphocytic leukemia (CLL), a B-cell malignancy. It compares treatment combinations to improve patient outcomes and quality of life.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Chronic lymphocytic leukemia (CLL) involves abnormal B-lymphocyte proliferation, impacting older adults.
- CLL patients face increased risks of infections and secondary cancers due to immune dysregulation.
- Immunotherapy has significantly improved prognosis and treatment for CLL.
Purpose of the Study:
- To review and analyze current immunotherapeutic strategies for CLL.
- To evaluate the efficacy, benefits, and drawbacks of existing treatments.
- To guide the selection of personalized treatment regimens and compare therapeutic combinations.
Main Methods:
- Systematic literature review of immunotherapies for CLL.
- Analysis of clinical trial data and treatment outcomes.
- Comparative assessment of different immunotherapeutic approaches and combinations.
Main Results:
- Immunotherapy has transformed CLL treatment, offering improved survival rates.
- Various immunotherapeutic agents and combinations show distinct efficacy profiles.
- Understanding treatment limitations is crucial for optimizing patient care.
Conclusions:
- Current immunotherapies offer substantial benefits for CLL patients.
- Tailoring treatment strategies based on individual needs enhances prognosis.
- Further research into therapeutic combinations aims to maximize patient survival and quality of life.
Abstract:
Chronic lymphocytic leukemia (CLL) is characterized as a clonal proliferation of mature B lymphocytes with distinct immunophenotypic traits, predominantly affecting the middle-aged and elderly population. This condition is marked by an accumulation of lymphocytes within the peripheral blood, bone marrow, spleen, and lymph nodes. The associated immune dysregulation predisposes CLL patients to a higher risk of secondary malignancies and infections, which significantly contribute to morbidity and mortality rates. The advent of immunotherapy has revolutionized the prognosis of CLL, advancing treatment modalities and offering substantial benefits to patient outcomes. This review endeavors to synthesize and scrutinize the efficacy, merits, and limitations of the current immunotherapeutic strategies for CLL. The aim is to inform the selection of optimal treatment regimens tailored to individual patient needs. Furthermore, the review juxtaposes various therapeutic combinations to elucidate the comparative advantages of each approach, with the ultimate objective of enhancing patient prognosis and quality of life.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:20Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...